Product menu

SHINGRIX mechanism of action

SHINGRIX IS DESIGNED TO INDUCE CELLULAR AND HUMORAL IMMUNE RESPONSES TO VZV1*

SHINGRIX is the first and only shingles vaccine to combine two components, a non-live antigen with an Adjuvant System.1,2*

SHINGRIX Mechanism of Action SHINGRIX Mechanism of Action

VZV = varicella zoster virus
* Clinical significance has not been established.

Learn more about the design of SHINGRIX

Discover the components and the mechanism of action of SHINGRIX.

Patient icon

Meet the patients that are eligible to receive SHINGRIX

Nearly everyone ≥50 years old should be protected against shingles.3

Learn more
Virus icon

What was shown to be the dominant driver of shingles?

Learn about age-related decline in immunity.4

Learn more
Cross icon

The safety profile of SHINGRIX was extensively studied in two large phase III clinical trials

Learn more about the safety profile of SHINGRIX.1

Learn more

References

  1. SHINGRIX Product Monograph. GlaxoSmithKline Inc., June 3, 2020.
  2. Lal H et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015;372(22):2087-2096.
  3. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html.
  4. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1-30.

Trademarks are owned by or licensed to the GSK group of companies.

©2021 GSK Group of Companies or its licensor.

PM-CA-SGX-WCNT-210001 | November 2021